Skip to content

Clinical trials

Fuchs' Endothelial Dystrophy trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Fuchs' Endothelial Dystrophy Phase: Not applicable Clear all

31 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20061
20081
20101
20111
20124
20131
20143
20161
20172
20181
20192
20201
20224
20241
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Unknown status6
Recruiting5
Not yet recruiting2
Withdrawn1
Enrolling by invitation1
Terminated1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Case Western Reserve University2
Cornea Research Foundation of America2
University Eye Hospital, Freiburg2
Aarhus University Hospital1
Centre Hospitalier Universitaire de Saint Etienne1
Charite University, Berlin, Germany1
Dar El Oyoun Hospital1
EDUARD PEDEMONTE-SARRIAS1
Glostrup University Hospital, Copenhagen1
Klinikum Chemnitz gGmbH1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Fuchs' Endothelial Dystrophy31
Corneal Edema5
Cataract4
Iridocorneal Endothelial Syndrome2
Corneal Diseases1
Corneal Dystrophies, Hereditary1
Corneal Endothelial Cell Loss1
Keratoconus1
Vision Disorders1

Trials

Showing 51 to 31 of 31. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.